Molecular determinants of cetuximab efficacy

Vallböhmer, Daniel; Zhang, W.; Gordon, Michael A.; Yang, Dongyun; Yun, Jie; Press, O.; Rhodes, Katrin E.; Iqbal, S.; Danenberg, K. D.

doi:10.1200/jco.2005.23.16_suppl.3551

Cited by 72 publications

(92 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The absence of predictive markers has increased the focus of other parts of signaling pathways related to the EGFR system. No clinical data are available, but at a preclinical level, it was found that high gene expression of VEGF was associated with resistance to EGFR inhibition (Vallbohmer et al, 2005). In line with these data, long-lasting reduced levels of serum VEGF was found upon treatment with Cx (Vincenzi et al, 2006b).…”

Section: Predicting Efficacy Of CX and Pamentioning

confidence: 83%

See 1 more Smart Citation

Current role of antibody therapy in patients with metastatic colorectal cancer

2007

View full text Add to dashboard Cite

Section: Predicting Efficacy Of CX and Pamentioning

confidence: 83%

“…There is a reliable rationale for combining VEGF and EGFR inhibitors (Vallbohmer et al, 2005;Vincenzi et al, 2006b). Preclinical studies confirmed a synergistic growth inhibition (Morelli et al, 2006;Tonra et al, 2006) and preliminary clinical data have already verified efficacy of the combination .…”

Section: Combination Of Targeted Therapiesmentioning

confidence: 99%

Current role of antibody therapy in patients with metastatic colorectal cancer

2007

View full text Add to dashboard Cite

“…However, tumour response was observed in colorectal tumours without an increase of EGFR copy number (Italiano et al, 2008) and discrepant results were observed when EGFR copy number was assessed by quantitative PCR and not by FISH (Vallbohmer et al, 2005;Lenz et al, 2006;Khambata-Ford et al, 2007).…”

Section: Pik3ca Mutations and Loss Of Pten Expressionmentioning

confidence: 96%

Oncogenic mutations as predictive factors in colorectal cancer

2010

View full text Add to dashboard Cite

“…Furthermore, current evidence suggests no association between a high EGFR cell surface expression and cetuximab response in colorectal cancer patients (15)(16)(17)(18)(19). Particularly in colorectal cancer, recent studies suggest that mutations of K-RAS gene are associated with nonresponsiveness to cetuximab, while amphiregulin and epiregulin overexpression may be markers of response (20)(21)(22)(23)(24).…”

Section: Discussionmentioning

confidence: 95%

“…ONCOLOGY REPORTS 21: 1023-1028, 2009 Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: A single institution retrospective analysis…”

Section: Introductionmentioning

confidence: 99%

Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: A single institution retrospective analysis

Orditura

Vita²,

Galizia³

et al. 2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. Several trials show a relationship between skin toxicity, response rate, and overall survival in cetuximabtreated patients. We analyzed our database to evaluate the importance of skin rash as a surrogate marker of favorable outcome in cancer patients referred to our institution in the last three years. We retrospectively analyzed 90 cetuximabtreated patients: 57 colon cancer patients, 10 NSCLC patients, 14 locally advanced esophageal cancer patients, and 9 miscellaneous. A significant correlation was observed between skin rash and response to therapy. Skin rash was experienced by 93% of PR and 100% of CR patients. The mean TTP was 184 days in patients showing skin rash and 94 days in patients without skin rash, respectively. On multivariate analysis, skin rash was demonstrated to be the only independent prognostic variable with regard to TTP. Patients who did not develop skin rash had a 2-fold greater likelihood to manifest tumor progression significantly earlier than patients who developed skin rash. In our series, a statistically significant correlation between rash, response rate, and TTP was demonstrated in 90 cetuximab-treated patients. Skin toxicity was confirmed as the only clinical variable able to predict the response to cetuximab.

show abstract

Molecular determinants of cetuximab efficacy

Cited by 72 publications

References 0 publications

Current role of antibody therapy in patients with metastatic colorectal cancer

Current role of antibody therapy in patients with metastatic colorectal cancer

Oncogenic mutations as predictive factors in colorectal cancer

Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: A single institution retrospective analysis

Contact Info

Product

Resources

About